HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
复制标题
HER2插入YVMA突变肺癌：悠久的自然史和对阿法替尼的反应。
DOI：
10.1016/j.lungcan.2015.10.025
复制
发表时间：
2015-12
期刊：
影响因子：
--
通讯作者：
Pavlakis N
中科院分区：
文献类型：
--
作者：
Li BT;Lee A;O'Toole S;Cooper W;Yu B;Chaft JE;Arcila ME;Kris MG;Pavlakis N
肺癌中的人表皮生长因子2（HER2，ERBB2）突变是对HER2靶向治疗有反应的致癌驱动因素。关于HER2突变型肺癌亚型对靶向药物的敏感性知之甚少。我们报告了1例携带12个碱基对插入YVMA（p.A775_G776insYVMA）的HER2突变型肺癌患者，该患者有长期自然病史，对阿法替尼有持久的部分缓解。我们证明，阿法替尼在携带20号外显子YVMA插入（最常见的变异）的HER2突变型肺癌患者中具有活性。
Human epidermal growth factor 2 (HER2, ERBB2) mutations in lung cancers are oncogenic drivers that respond to HER2 targeted therapies. Little is known about the sensitivity of subtypes of HER2 mutant lung cancers to targeted agents. We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib. We demonstrate that afatinib has activity in patients with HER2 mutant lung cancers with exon 20 YVMA insertions, the most common variant.